Antigen-specific immunotherapy with thyrotropin receptor peptides in Graves' hyperthyroidism: a phase I study
Higham, Claire E
AffiliationInstitute for Genetic Medicine, Newcastle University, and Newcastle Hospitals NHS Trust, Newcastle upon Tyne, United Kingdom
MetadataShow full item record
AbstractBackground: Graves' disease is one of the most common autoimmune conditions, but treatment remains imperfect. This study explores the first-in-human use of antigen-specific immunotherapy with a combination of two thyrotropin receptor (TSHR) peptides (termed ATX-GD-59) in Graves' hyperthyroidism. Methods: Twelve participants (11 female) with previously untreated mild to moderate Graves' hyperthyroidism were enrolled in a Phase I open label trial to receive 10 doses of ATX-GD-59 administered intradermally over an 18-week period. Adverse events, tolerability, changes in serum free thyroid hormones, and TSHR autoantibodies were measured. Results: Ten subjects received all 10 doses of ATX-GD-59, five (50%) of whom had free triiodothyronine within the reference interval by the 18-week visit. Two further subjects had improved free thyroid hormones by the end of the study (7/10 responders), whereas three subjects showed worsening thyrotoxicosis during the study. Serum TSHR autoantibody concentrations reduced during the study and correlated with changes in free thyroid hormones (r?=?0.85, p?=?0.002 for TSHR autoantibody vs. free triiodothyronine). Mild injection-site swelling and pain were the most common adverse events. Conclusions: These preliminary data suggest that ATX-GD-59 is a safe and well-tolerated treatment. The improvement in free thyroid hormones in 70% of subjects receiving the medication suggests potential efficacy as a novel treatment for Graves' hyperthyroidism.
CitationPearce SHS, Dayan C, Wraith DC, Barrell K, Olive N, Jansson L, et al. Antigen-specific immunotherapy with thyrotropin receptor peptides in Graves' hyperthyroidism: a phase I study. Thyroid. 2019.
- Critical Differences between Induced and Spontaneous Mouse Models of Graves' Disease with Implications for Antigen-Specific Immunotherapy in Humans.
- Authors: Rapoport B, Banuelos B, Aliesky HA, Hartwig Trier N, McLachlan SM
- Issue date: 2016 Dec 15
- Persistent Graves' hyperthyroidism despite rapid negative conversion of thyroid-stimulating hormone-binding inhibitory immunoglobulin assay results: a case report.
- Authors: Ohara N, Kaneko M, Kitazawa M, Uemura Y, Minagawa S, Miyakoshi M, Kaneko K, Kamoi K
- Issue date: 2017 Feb 6
- Thyrotropin-producing pituitary adenoma simultaneously existing with Graves' disease: a case report.
- Authors: Arai N, Inaba M, Ichijyo T, Kagami H, Mine Y
- Issue date: 2017 Jan 6
- Thyrotropin-blocking autoantibodies and thyroid-stimulating autoantibodies: potential mechanisms involved in the pendulum swinging from hypothyroidism to hyperthyroidism or vice versa.
- Authors: McLachlan SM, Rapoport B
- Issue date: 2013 Jan
- Serum autotaxin levels are associated with Graves' disease.
- Authors: Nojiri T, Kurano M, Araki O, Nakawatari K, Nishikawa M, Shimamoto S, Igarashi K, Kano K, Aoki J, Kihara S, Murakami M, Yatomi Y
- Issue date: 2019 May 28